DE69527617D1 - Verfahren zur racematspaltung von etodolac unter verwendung von glucamin-derivaten - Google Patents

Verfahren zur racematspaltung von etodolac unter verwendung von glucamin-derivaten

Info

Publication number
DE69527617D1
DE69527617D1 DE69527617T DE69527617T DE69527617D1 DE 69527617 D1 DE69527617 D1 DE 69527617D1 DE 69527617 T DE69527617 T DE 69527617T DE 69527617 T DE69527617 T DE 69527617T DE 69527617 D1 DE69527617 D1 DE 69527617D1
Authority
DE
Germany
Prior art keywords
etodolac
pct
glucamine
sec
glucamine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69527617T
Other languages
English (en)
Other versions
DE69527617T2 (de
Inventor
Michael Adger
Conrad Dyer
Martin Woods
Francis Andrews
Helen Frances Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sosei R&D Ltd
Original Assignee
Arakis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9407225A external-priority patent/GB9407225D0/en
Priority claimed from GBGB9501455.1A external-priority patent/GB9501455D0/en
Application filed by Arakis Ltd filed Critical Arakis Ltd
Publication of DE69527617D1 publication Critical patent/DE69527617D1/de
Application granted granted Critical
Publication of DE69527617T2 publication Critical patent/DE69527617T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
DE69527617T 1994-04-12 1995-04-11 Verfahren zur racematspaltung von etodolac unter verwendung von glucamin-derivaten Expired - Fee Related DE69527617T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9407225A GB9407225D0 (en) 1994-04-12 1994-04-12 Chiroscience limited
GBGB9501455.1A GB9501455D0 (en) 1995-01-25 1995-01-25 Analgesic agent and its use
PCT/GB1995/000857 WO1995027713A1 (en) 1994-04-12 1995-04-11 Process for the resolution of etodolac using glucamine derivatives

Publications (2)

Publication Number Publication Date
DE69527617D1 true DE69527617D1 (de) 2002-09-05
DE69527617T2 DE69527617T2 (de) 2003-04-10

Family

ID=26304688

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69527617T Expired - Fee Related DE69527617T2 (de) 1994-04-12 1995-04-11 Verfahren zur racematspaltung von etodolac unter verwendung von glucamin-derivaten

Country Status (9)

Country Link
US (1) US5811558A (de)
EP (1) EP0755398B1 (de)
JP (1) JPH09511516A (de)
AT (1) ATE221533T1 (de)
AU (1) AU2220695A (de)
DE (1) DE69527617T2 (de)
ES (1) ES2177644T3 (de)
NO (1) NO964346L (de)
WO (1) WO1995027713A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574183A (en) * 1995-01-24 1996-11-12 Albemarle Corporation Preparation of optically active aliphatic carboxylic acids
US6399093B1 (en) 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7129262B2 (en) * 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7361680B2 (en) * 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7151100B1 (en) * 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
GB0007239D0 (en) * 2000-03-24 2000-05-17 Nycomed Imaging As Use
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
US7601846B2 (en) * 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
US20030232794A1 (en) * 2001-06-26 2003-12-18 Cottam Howard B. Use of STAT-6 inhibitors as therapeutic agents
GB0206505D0 (en) * 2002-03-19 2002-05-01 Euro Celtique Sa Pharmaceutical combination
WO2004026116A2 (en) * 2002-09-19 2004-04-01 The Regents Of The University Of California Use of etodoclac to treat hyperplasia
ITMI20031471A1 (it) 2003-07-18 2005-01-19 Chemi Spa Processo per la racemizzazione dell'acido etodolico
DK3056492T3 (da) 2004-10-08 2021-12-13 Abbvie Inc Megluminsalt og krystallinke former deraf af et lægemiddel (delafloxacin)
PT1868581E (pt) * 2005-04-11 2012-06-22 Abbott Lab Composições farmacêuticas que possuem perfis de dissolução melhorados para fármacos pouco solúveis
ITMI20060894A1 (it) 2006-05-05 2007-11-06 Univ Catania Ciclodestrine funzionalizzate con etodolac come agenti di rilascio sito specifico
WO2007142755A2 (en) 2006-05-31 2007-12-13 The Regents Of The University Of California Purine analogs
CN102850204B (zh) * 2011-06-29 2015-08-19 徐州医学院 一种(s)-2-芳基丙酸类非甾体抗炎药的拆分方法
WO2013169218A1 (en) 2012-05-08 2013-11-14 Mahmut Bilgic Pharmaceutical compositions of s-etodolac

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520203A (en) * 1983-08-16 1985-05-28 American Home Products Corporation Resolution of (±)-1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid using cinchonine
US4501899A (en) * 1983-08-16 1985-02-26 American Home Products Corporation Resolution of (+)-1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid using cholesteryl aniline
US4544757A (en) * 1984-02-16 1985-10-01 American Home Products Corporation Process for the resolution of pyrano[3,4-b]indole-1-acetic acids
IT1207994B (it) * 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
EP0408496A3 (en) * 1989-07-12 1992-07-01 Ciba-Geigy Ag Solid dosage form for pharmaceutical substances
US5256293A (en) * 1991-09-20 1993-10-26 Research Corporation Technologies, Inc. Separation of enantiomers of non-steroidal anti-inflammatory drugs and chiral selector therefor

Also Published As

Publication number Publication date
EP0755398B1 (de) 2002-07-31
ES2177644T3 (es) 2002-12-16
JPH09511516A (ja) 1997-11-18
ATE221533T1 (de) 2002-08-15
AU2220695A (en) 1995-10-30
EP0755398A1 (de) 1997-01-29
NO964346D0 (no) 1996-10-11
NO964346L (no) 1996-12-11
DE69527617T2 (de) 2003-04-10
US5811558A (en) 1998-09-22
WO1995027713A1 (en) 1995-10-19

Similar Documents

Publication Publication Date Title
DE69527617D1 (de) Verfahren zur racematspaltung von etodolac unter verwendung von glucamin-derivaten
DE69406936D1 (de) Verfahren zur herstellung von amino-1-hydroxy-alkyliden-1,1-bisphosphonsäuren
ES2173194T3 (es) Procedimiento de racemizacion utilizado para la preparacion de levobupivacaina y sus analogos.
DE59609103D1 (de) Verfahren zur racematspaltung
ATE257142T1 (de) Verfahren zur racematspaltung von 2- hydroxypropionsäuren
ES2126313T3 (es) Hidrolisis enzimatica de los 4-metiltiobutironitrilos.
DE69622692T2 (de) Verfahren zur herstellung von ungesättigten nitrilen
ATE227725T1 (de) Verfahren zur herstellung von galanthanin
DE69607113D1 (de) Verfahren zur Racemisierung von optisch aktiven 1-Phenylethylamin-Derivaten
DE69713163T2 (de) Verfahren zur herstellung von enantiomerisch angereicherten n-acylazetidin-2-carbonsäuren
DE69603419T2 (de) Verfahren zur Herstellung von optisch aktiven Amiden
ATE132535T1 (de) Verfahren zur diskontinuierlichen herstellung von l-carnitin auf mikrobiologischem weg
DE69707639D1 (de) Verfahren zur herstellung einer aktivierten aminosäure
DE69519388T2 (de) Verfahren zur herstellung von 2-(omega-alkoxycarbonylalkanoyl)-4-butanolid und langkettiger omega-hydroxycarbonsäure
DE69620437D1 (de) Verfahren zur herstellung von optisch aktivem 2-substituiertem tetrahydropyran-4-on
ATE200776T1 (de) Verfahren zur herstellung von 2,4,5-tribrompyrrol-3-carbonitril
DE69602780T2 (de) Verfahren zur Herstellung von 3-Chlorpropionsäure
DE69407789T2 (de) Verfahren zur herstellung von (s)-4-aminohepta-5,6-diencarbon-säure und intermediate
DE3769442D1 (de) Neues verfahren zur herstellung von optisch aktiven carbacyclin-zwischenprodukten.
ATE187958T1 (de) Verfahren zur herstellung von levobupivacain und analogue aus l-lysin
DE68905073D1 (de) Verfahren zur herstellung von racemischen cyclopropancarbonsaeurehalogeniden.
ATE205471T1 (de) Verfahren zur herstellung von enantiomeren der aminoalkylaminophenylpropansäure

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee